Oct 25, 2016
Boston Biomedical starts phase III study of Napabucasin Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stemness pathways, announced dosing of the first patient in CanStem303C, a new global phase III study investigating napabucasin in combination with standard of...
Read More...
Oct 21, 2016
The recent outbreak of Dengue in Asia has brought forward the threat of mosquito bite into the spotlight again. Dengue is a kind of viral infection caused by mosquito bite, and the disease has now become a threat to about 390 million people, as these many are estimated to be infected each year. This incidence of inf...
Read More...
Aug 27, 2014
DelveInsight is helping worldwide Pharmaceutical companies with its Market Intelligence Reports. VISIT OUR WEBSITE Infectious Diseases and Vaccines The infectious disease (ID) vaccine pipeline is rich and robust. However, indications such as HIV, Tuberculosis and HCV have high demand for the development of a fi...
Read More...
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Aug 05, 2026
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Newsletter/Whitepaper